Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Hansa Biopharma AB ( (SE:HNSA) ) has issued an update.
Hansa Biopharma announced that its CEO, Renée Aguiar-Lucander, will speak at the BIO International Convention in Boston, focusing on unlocking investment opportunities in European biotech. This participation highlights Hansa’s strategic efforts to engage with potential investors and stakeholders, potentially enhancing its industry positioning and expanding its market reach.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for rare immunological conditions. The company utilizes its proprietary IgG-cleaving enzyme technology platform to address unmet medical needs in autoimmune diseases, gene therapy, and transplantation. Its portfolio includes imlifidase, an IgG antibody-cleaving enzyme therapy, and HNSA-5487, a next-generation IgG cleaving molecule.
Average Trading Volume: 162,013
Current Market Cap: SEK1.78B
Learn more about HNSA stock on TipRanks’ Stock Analysis page.